How has been the historical performance of Nath Bio-Genes?

Answer:The historical performance of Nath Bio-Genes shows a consistent growth trend in net sales and profits over the past four years, with net sales increasing from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25. The total operating income followed the same trajectory, reaching 364.91 Cr in Mar'25. The company has managed to maintain a stable operating profit, with PBDIT rising from 39.03 Cr in Mar'22 to 54.35 Cr in Mar'25, although the operating profit margin has slightly decreased from 14.99% in Mar'24 to 13.65% in Mar'25. Profit before tax has also shown improvement, moving from a loss of 63.43 Cr in Mar'22 to a profit of 40.04 Cr in Mar'25. Profit after tax similarly improved from a loss of 67.39 Cr in Mar'22 to a profit of 38.06 Cr in Mar'25, reflecting a PAT margin of 10.43% in the latest year. The earnings per share (EPS) have also increased, reaching 20.32 in Mar'25 compared to a negative EPS of -35.46 in Mar'22.

Breakdown:
Nath Bio-Genes has demonstrated significant growth in its financial performance over the years. Net sales rose from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25, indicating a strong upward trend. The total operating income mirrored this growth, reaching 364.91 Cr in the latest fiscal year. Operating profit, measured by PBDIT, increased from 39.03 Cr in Mar'22 to 54.35 Cr in Mar'25, although the operating profit margin has slightly declined over the years. The company turned around its profitability, with profit before tax improving from a loss of 63.43 Cr in Mar'22 to a profit of 40.04 Cr in Mar'25, and profit after tax following suit from a loss of 67.39 Cr to a profit of 38.06 Cr. This resulted in a PAT margin of 10.43% in Mar'25. Additionally, the earnings per share have significantly improved, showcasing the company's recovery and growth trajectory.